Novartis plops down $9.7 billion for The Medicines Co.
Well, the rumors have borne fruit: Novartis will acquire The Medicines Company for a whopping $9.7 billion, the companies announced Sunday evening. The deal could buoy Novartis’s cardiovascular business by giving it control of an experimental RNAi drug called inclisiran that aims to lower LDL cholesterol by targeting the PCSK9 protein in the liver.
Novartis said that inclisiran, a first-in-class drug, “could become one of the largest products by sales” in its portfolio. Inclisiran is in Phase 3 trials in conjunction with Alnylam Pharmaceuticals.
As STAT's Matthew Herper notes, the deal also marks a triumphant final act for Clive Meanwell, who founded The Medicines Company in 1996 and ran it through a quarter-century rollercoaster ride that saw the firm become a Wall Street darling, fall from favor, and, in the past year, reach new heights.
Read more.
As STAT's Matthew Herper notes, the deal also marks a triumphant final act for Clive Meanwell, who founded The Medicines Company in 1996 and ran it through a quarter-century rollercoaster ride that saw the firm become a Wall Street darling, fall from favor, and, in the past year, reach new heights.
Read more.
No hay comentarios:
Publicar un comentario